Matches in Wikidata for { <http://www.wikidata.org/entity/Q91616178> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q91616178 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91616178 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91616178 description "scientific article published on 29 November 2019" @default.
- Q91616178 description "wetenschappelijk artikel" @default.
- Q91616178 description "наукова стаття, опублікована 29 листопада 2019" @default.
- Q91616178 name "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)" @default.
- Q91616178 name "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)" @default.
- Q91616178 type Item @default.
- Q91616178 label "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)" @default.
- Q91616178 label "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)" @default.
- Q91616178 prefLabel "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)" @default.
- Q91616178 prefLabel "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)" @default.
- Q91616178 P1104 Q91616178-B3D3ECE2-70E9-4791-A4AB-22FCD7A917B5 @default.
- Q91616178 P1433 Q91616178-6FE0A038-CAA3-49F1-8B1F-FEE5A75D81FE @default.
- Q91616178 P1476 Q91616178-D0A4D53E-C4DB-47FF-9C11-EBB4A3E29C2D @default.
- Q91616178 P2093 Q91616178-0656BE44-CA59-41E9-B6B7-0BEFE8633377 @default.
- Q91616178 P2093 Q91616178-2C204109-7E90-49DF-B971-CC0F83B6A44E @default.
- Q91616178 P2093 Q91616178-2F4407AB-2148-44C0-A602-E941E607AE42 @default.
- Q91616178 P2093 Q91616178-379D4683-6E23-416B-943C-5F1210598EA7 @default.
- Q91616178 P2093 Q91616178-581A382C-E56C-4D3D-B642-C9C98A528EAC @default.
- Q91616178 P2093 Q91616178-67A1A3CC-DCB9-4982-A0BD-21ECD4566DCB @default.
- Q91616178 P2093 Q91616178-9754C3B1-8A73-4248-A6AF-F639EBE60549 @default.
- Q91616178 P2093 Q91616178-A01E05C1-CA0E-44AB-A568-F02368F09A4B @default.
- Q91616178 P2093 Q91616178-B46CC05A-BBF7-48AD-B89F-1112EA7A00B3 @default.
- Q91616178 P2093 Q91616178-F53F197C-723E-442F-8BD6-7ADB9EA2EF83 @default.
- Q91616178 P2093 Q91616178-F68C2787-CC52-4826-B809-DCFA62CEAF6C @default.
- Q91616178 P304 Q91616178-94BDD457-93F9-410D-ADAA-0C04E9D05BE6 @default.
- Q91616178 P31 Q91616178-0BB1E9FB-1CC6-40B1-B9C2-BFE28DDF7B9A @default.
- Q91616178 P356 Q91616178-8E4949CA-D21A-4274-910B-AD85152DCE1A @default.
- Q91616178 P433 Q91616178-96D0EC8B-0A7F-4308-96FA-D3D495118D2D @default.
- Q91616178 P478 Q91616178-1AC74191-E297-476D-805E-EAFA56665847 @default.
- Q91616178 P577 Q91616178-3D2453F7-E52E-44B5-8267-9A22D5BED138 @default.
- Q91616178 P698 Q91616178-8EAC0A04-3D87-4D6A-A8EE-5A6B0D297E4F @default.
- Q91616178 P921 Q91616178-AC7722D4-2929-470A-94EE-FBC64D209EEB @default.
- Q91616178 P356 J.JAAD.2019.06.1313 @default.
- Q91616178 P698 31791824 @default.
- Q91616178 P1104 "+8" @default.
- Q91616178 P1433 Q15757046 @default.
- Q91616178 P1476 "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)" @default.
- Q91616178 P2093 "Ava Shamban" @default.
- Q91616178 P2093 "Conor Gallagher" @default.
- Q91616178 P2093 "Daniel Snyder" @default.
- Q91616178 P2093 "Gill Shears" @default.
- Q91616178 P2093 "Joel Schlessinger" @default.
- Q91616178 P2093 "Joely Kaufman-Janette" @default.
- Q91616178 P2093 "Nowell Solish" @default.
- Q91616178 P2093 "Roman G Rubio" @default.
- Q91616178 P2093 "Steve Yoelin" @default.
- Q91616178 P2093 "Vince Bertucci" @default.
- Q91616178 P2093 "Yan Liu" @default.
- Q91616178 P304 "838-845" @default.
- Q91616178 P31 Q13442814 @default.
- Q91616178 P356 "10.1016/J.JAAD.2019.06.1313" @default.
- Q91616178 P433 "4" @default.
- Q91616178 P478 "82" @default.
- Q91616178 P577 "2019-11-29T00:00:00Z" @default.
- Q91616178 P698 "31791824" @default.
- Q91616178 P921 Q269829 @default.